Report #2830014

Received Mar 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: MI
Recovered: Unknown
Vaccinated: Feb 26, 2025
Onset: Feb 26, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	BP74J	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received the second dose of Shingrix 12 days after the first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 76-year-old male patient who received Herpes zoster (Shingrix) (batch number BP74J, expiry date 15-NOV-2026) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 26-FEB-2025, the patient received the 2nd dose of Shingrix. On 26-FEB-2025, an unknown time after receiving Shingrix and Shingrix, the patient experienced drug dose administration interval too short (Verbatim: received the second dose of Shingrix 12 days after the first dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 27-FEB-2025 A pharmacist reported that a patient received the second dose of Shingrix 12 days after the first dose, which led to shortening of vaccine schedule. The reporter asked that the second dose considered was valid.